Status:
COMPLETED
Treatment With Namenda in Women at Risk for Cognitive Decline
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Forest Laboratories
Conditions:
Dementia
Eligibility:
FEMALE
50-65 years
Phase:
NA
Brief Summary
This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already bee...
Detailed Description
Memantine is a well-tolerated moderate-affinity, uncompetitive, voltage-dependent NMDA receptor antagonist that is shown to improve cognition and behavior in mild to moderate and moderate to severe Al...
Eligibility Criteria
Inclusion
- :
- Women between the ages of 50-65
- Willing to sign Human Subjects Protection Consent Form
- Personal or family history of mood disorder
- Hypothyroidism
- Diabetes
- Family history of Alzheimer's disease
Exclusion
- Possible or probable Alzheimer's disease or dementia
- History of cerebrovascular disease
- History of myocardial infarction within the previous year
- History of unstable heart disease
- Uncontrolled hypertension
- Less than 8 years of education
- English as a 2nd language
- Uncorrected vision or hearing deficits
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00242632
Start Date
June 1 2004
End Date
December 1 2009
Last Update
June 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305